Autoimmune hepatitis

Epidemiology, prognosis and follow-up

Tutkimustuotos: OpinnäyteVäitöskirjaArtikkelikokoelma

Kuvaus

Aims: This thesis includes one study (Study I) focused on epidemiological data regarding autoimmune hepatitis (AIH) and three studies (Studies II-IV) on follow-up of AIH. Patients and methods: Patients with AIH code K73.2 or K75.4 with special reimbursement in the Social Insurance Institution of Finland registry were included. Data from the Finnish cancer register were used to calculate standardized mortality ratios (Study I). All patients with AIH diagnosis in Helsinki University Hospital were included in the retrospective study of the impact of liver histology on disease progression (Study II). Twelve patients with AIH were investigated with magnetic resonance spectroscopy, liver biopsy, and transient elastography (Study III). Follow-up biopsies of all Finnish liver transplant recipients with AIH as an indication for transplantation were combined with clinical data to evaluate the prognosis and risk factors for AIH recurrence and graft loss (Study IV). Results: We showed that the median AIH incidence between 1995 and 2015 was 1.0/100,000/year (1.2/100,000/year in women and 0.38/100,000/year in men) and increased from 0.28/100,000 to 1.0/100,000 during the study period. The prevalence of AIH in 2015 was 14/100,000, 23/100,000 in women and 6.6/100,000 in men). The standardised mortality ratio was increased in all age groups and both genders. The most prevalent excessive causes of mortality when compared to the standard population were hepatocellular carcinoma, liver cirrhosis, and AIH per se (Study I). We identified the following prognostic variables for advancing fibrosis or cirrhosis in follow-up biopsies: interface or total inflammation, necrosis, cholestasis, or rosette formation in the baseline biopsy. If inflammation in the follow-up biopsies was constantly grade two or more in the Metavir scale, the hazard ratio (HR) for cirrhosis was 5.1, (95 % Confidence interval (CI) 1.6-16.2), p
Alkuperäiskielienglanti
Valvoja/neuvonantaja
  • Färkkilä, Martti, Valvoja
  • Arkkila, Perttu, Valvoja
Myöntöpäivämäärä10 toukokuuta 2019
JulkaisupaikkaHelsinki
Kustantaja
Painoksen ISBN978-951-51-5134-6
Sähköinen ISBN978-951-51-5135-3
TilaJulkaistu - 2019
OKM-julkaisutyyppiG5 Tohtorinväitöskirja (artikkeli)

Tieteenalat

  • 3121 Sisätaudit

Lainaa tätä

Puustinen, Lauri. / Autoimmune hepatitis : Epidemiology, prognosis and follow-up. Helsinki : Helsingin yliopisto, 2019. 69 Sivumäärä
@phdthesis{342cd37b127241ef9c949c9b1e5e381e,
title = "Autoimmune hepatitis: Epidemiology, prognosis and follow-up",
abstract = "Aims: This thesis includes one study (Study I) focused on epidemiological data regarding autoimmune hepatitis (AIH) and three studies (Studies II-IV) on follow-up of AIH. Patients and methods: Patients with AIH code K73.2 or K75.4 with special reimbursement in the Social Insurance Institution of Finland registry were included. Data from the Finnish cancer register were used to calculate standardized mortality ratios (Study I). All patients with AIH diagnosis in Helsinki University Hospital were included in the retrospective study of the impact of liver histology on disease progression (Study II). Twelve patients with AIH were investigated with magnetic resonance spectroscopy, liver biopsy, and transient elastography (Study III). Follow-up biopsies of all Finnish liver transplant recipients with AIH as an indication for transplantation were combined with clinical data to evaluate the prognosis and risk factors for AIH recurrence and graft loss (Study IV). Results: We showed that the median AIH incidence between 1995 and 2015 was 1.0/100,000/year (1.2/100,000/year in women and 0.38/100,000/year in men) and increased from 0.28/100,000 to 1.0/100,000 during the study period. The prevalence of AIH in 2015 was 14/100,000, 23/100,000 in women and 6.6/100,000 in men). The standardised mortality ratio was increased in all age groups and both genders. The most prevalent excessive causes of mortality when compared to the standard population were hepatocellular carcinoma, liver cirrhosis, and AIH per se (Study I). We identified the following prognostic variables for advancing fibrosis or cirrhosis in follow-up biopsies: interface or total inflammation, necrosis, cholestasis, or rosette formation in the baseline biopsy. If inflammation in the follow-up biopsies was constantly grade two or more in the Metavir scale, the hazard ratio (HR) for cirrhosis was 5.1, (95 {\%} Confidence interval (CI) 1.6-16.2), p",
keywords = "Hepatitis, Autoimmune, +diagnosis, +epidemiology, +mortality, Biopsy, Disease Progression, Elasticity Imaging Techniques, Graft Survival, Hepatocytes, +metabolism, Inflammation, Liver Cirrhosis, Liver Neoplasms, Liver Transplantation, Magnetic Resonance Spectroscopy, Risk Factors, Liver, +pathology, Fibrosis, Immunosuppressive Agents, Cholestasis, 3121 Internal medicine",
author = "Lauri Puustinen",
note = "M1 - 69 s. + liitteet",
year = "2019",
language = "English",
isbn = "978-951-51-5134-6",
series = "Dissertationes scholae doctoralis ad sanitatem investigandam Universitatis Helsinkiensis",
publisher = "Helsingin yliopisto",
number = "28/2019",
address = "Finland",

}

Autoimmune hepatitis : Epidemiology, prognosis and follow-up. / Puustinen, Lauri.

Helsinki : Helsingin yliopisto, 2019. 69 s.

Tutkimustuotos: OpinnäyteVäitöskirjaArtikkelikokoelma

TY - THES

T1 - Autoimmune hepatitis

T2 - Epidemiology, prognosis and follow-up

AU - Puustinen, Lauri

N1 - M1 - 69 s. + liitteet

PY - 2019

Y1 - 2019

N2 - Aims: This thesis includes one study (Study I) focused on epidemiological data regarding autoimmune hepatitis (AIH) and three studies (Studies II-IV) on follow-up of AIH. Patients and methods: Patients with AIH code K73.2 or K75.4 with special reimbursement in the Social Insurance Institution of Finland registry were included. Data from the Finnish cancer register were used to calculate standardized mortality ratios (Study I). All patients with AIH diagnosis in Helsinki University Hospital were included in the retrospective study of the impact of liver histology on disease progression (Study II). Twelve patients with AIH were investigated with magnetic resonance spectroscopy, liver biopsy, and transient elastography (Study III). Follow-up biopsies of all Finnish liver transplant recipients with AIH as an indication for transplantation were combined with clinical data to evaluate the prognosis and risk factors for AIH recurrence and graft loss (Study IV). Results: We showed that the median AIH incidence between 1995 and 2015 was 1.0/100,000/year (1.2/100,000/year in women and 0.38/100,000/year in men) and increased from 0.28/100,000 to 1.0/100,000 during the study period. The prevalence of AIH in 2015 was 14/100,000, 23/100,000 in women and 6.6/100,000 in men). The standardised mortality ratio was increased in all age groups and both genders. The most prevalent excessive causes of mortality when compared to the standard population were hepatocellular carcinoma, liver cirrhosis, and AIH per se (Study I). We identified the following prognostic variables for advancing fibrosis or cirrhosis in follow-up biopsies: interface or total inflammation, necrosis, cholestasis, or rosette formation in the baseline biopsy. If inflammation in the follow-up biopsies was constantly grade two or more in the Metavir scale, the hazard ratio (HR) for cirrhosis was 5.1, (95 % Confidence interval (CI) 1.6-16.2), p

AB - Aims: This thesis includes one study (Study I) focused on epidemiological data regarding autoimmune hepatitis (AIH) and three studies (Studies II-IV) on follow-up of AIH. Patients and methods: Patients with AIH code K73.2 or K75.4 with special reimbursement in the Social Insurance Institution of Finland registry were included. Data from the Finnish cancer register were used to calculate standardized mortality ratios (Study I). All patients with AIH diagnosis in Helsinki University Hospital were included in the retrospective study of the impact of liver histology on disease progression (Study II). Twelve patients with AIH were investigated with magnetic resonance spectroscopy, liver biopsy, and transient elastography (Study III). Follow-up biopsies of all Finnish liver transplant recipients with AIH as an indication for transplantation were combined with clinical data to evaluate the prognosis and risk factors for AIH recurrence and graft loss (Study IV). Results: We showed that the median AIH incidence between 1995 and 2015 was 1.0/100,000/year (1.2/100,000/year in women and 0.38/100,000/year in men) and increased from 0.28/100,000 to 1.0/100,000 during the study period. The prevalence of AIH in 2015 was 14/100,000, 23/100,000 in women and 6.6/100,000 in men). The standardised mortality ratio was increased in all age groups and both genders. The most prevalent excessive causes of mortality when compared to the standard population were hepatocellular carcinoma, liver cirrhosis, and AIH per se (Study I). We identified the following prognostic variables for advancing fibrosis or cirrhosis in follow-up biopsies: interface or total inflammation, necrosis, cholestasis, or rosette formation in the baseline biopsy. If inflammation in the follow-up biopsies was constantly grade two or more in the Metavir scale, the hazard ratio (HR) for cirrhosis was 5.1, (95 % Confidence interval (CI) 1.6-16.2), p

KW - Hepatitis, Autoimmune

KW - +diagnosis

KW - +epidemiology

KW - +mortality

KW - Biopsy

KW - Disease Progression

KW - Elasticity Imaging Techniques

KW - Graft Survival

KW - Hepatocytes

KW - +metabolism

KW - Inflammation

KW - Liver Cirrhosis

KW - Liver Neoplasms

KW - Liver Transplantation

KW - Magnetic Resonance Spectroscopy

KW - Risk Factors

KW - Liver

KW - +pathology

KW - Fibrosis

KW - Immunosuppressive Agents

KW - Cholestasis

KW - 3121 Internal medicine

M3 - Doctoral Thesis

SN - 978-951-51-5134-6

T3 - Dissertationes scholae doctoralis ad sanitatem investigandam Universitatis Helsinkiensis

PB - Helsingin yliopisto

CY - Helsinki

ER -

Puustinen L. Autoimmune hepatitis: Epidemiology, prognosis and follow-up. Helsinki: Helsingin yliopisto, 2019. 69 s. (Dissertationes scholae doctoralis ad sanitatem investigandam Universitatis Helsinkiensis; 28/2019).